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“Poison is in everything, and no thing is without poison.  
The dosage makes it either a poison or a remedy.” 
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Abbreviations  
ABT   = 1-aminobenzotriazole  
ADME  = Absorption, distribution, metabolism, and excretion  
AhR  = Aryl hydrocarbon receptor  
AO  = Aldehyde oxidase 
AUC  = Area under the blood concentration-time curve  
AUCi.a. = AUC following intra-arterial dosing 
AUC0-inf = AUC from time zero to infinity  
AUCi.v.  = AUC following intravenous dosing  
CAR  = Constitutive androstane receptors 
CE  = Collision energy  
CES1  = Carboxylesterase 1 
CID  = Collision induced dissociation  
CLint,in vitro = In vitro intrinsic clearance  
CLint,organ = Intrinsic clearance of whole organ 
CLlung  = Lung clearance 
CLblood  = Blood clearance  
COPD  = Chronic obstructive pulmonary disease 
CV  = Cone voltage  
CYP  = Cytochrome P450  
DMSO = Dimethyl sulfoxide  
DOC  = Dynamic organ culture  
Elung  = In vivo extraction ratio in lung 
ESI  = Electrospray ionization  
EROD  = 7-ethoxy-resorufin-O-deethylase 
FMO  = Flavin-containing monooxygenase  
fu  = Unbound fraction of the drug in plasma 
fuinc  = Unbound fraction in microsomal incubations  
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fulung  = Fraction unbound in lung slices incubations  
GST  = Glutathione S-transferase 
HEPES = 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
i.a.  = Intra-arterial  
i.v.  = Intravenous  
Km  = Michaelis-Menten constant 
LC-MS/MS = Liquid chromatography-tandem mass spectrometry 
LLQ  = Lower Limit of Quantitation  
MEM  = Minimal essential medium 
MRM  = Multiple reaction monitoring  
MRT  = Mean residence time  
NADPH = β nicotinamide adenine dinucleotide phosphate reduced  
NAT  = N-acetyl transferase 
NCA  = Non-compartmental analysis  
PCLS   = Precision-cut lung slices  
PK  = Pharmacokinetic 
PXR  = Pregnane X receptors 
Qliver  = Liver blood flow  
Qlung  = Pulmonary blood flow  
Rb/p  = Blood/plasma ratio  
SD  = Sprague Dawley  
S.D.  = Standard deviation  
S.E:  = Standard error of the mean  
SDM  = Sulfadimethoxine 
SULT  = Sulfotransferase 
Λz  = Terminal disposition rate constant  
UDPGA = Uridine-diphosphate-glucuronic acid trisodium salt  
UGT  = Uridine 5’-diphosphoglucuronosyltransferase  
UPLC  = Ultra Performance Liquid Chromatography  
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Vmax  = Maximum rate of metabolism (limiting reaction velocity)  
Vss  = Volume of distribution at steady state 
WH  = Wistar Han  
4-MU  = 4-Methylumbelliferone 
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Chapter 1. Summary  
Drug metabolism involves the biochemical modification of pharmaceutical 
substances or xenobiotics by living organisms, usually through specialized 
enzymes. This process normally converts lipophilic chemicals into less potent, and 
more hydrophilic products that facilitates their elimination from the body (Mittal et 
al., 2015). However, these processes may also convert the drug into more lipophilic, 
more potent or even toxic metabolites (Macherey and Dansette, 2015). In order to 
design effective and safe dosage regimens, the pharmacology, toxicology, and 
drug-drug interactions of the drug and its metabolites should be thoroughly 
understood (Tillement and Tremblay, 2007). As a result, the study of drug 
metabolism is vital to the pharmaceutical industry. Drug metabolism is generally 
divided into two distinct phases. Phase I reactions include oxidation, reduction and 
hydrolysis which are mediated by enzymes such as cytochrome P450 (CYPs), 
flavin-containing monooxygenases (FMOs), aldehyde oxidase (AO) and various 
hydrolases (Shehata, 2010). In phase II metabolism, enzymes such as uridine 5’-
diphosphoglucuronosyltransferase (UGT), sulfotransferase, glutathione S-
transferase (GST) and N-acetyl transferase (NAT) catalyze the conjugation of drugs 
with endogenous molecules (Testa and Clement, 2015).  
Although the liver is the primary site of drug metabolism, other organs including 
skin, lungs, kidneys, and intestine also possess considerable metabolic capacity 
(Krishna and Klotz, 1994). Furthermore, drug-metabolizing enzymes are known to 
be expressed in the lungs, albeit to a lesser extent than in liver (Somers et al., 2007). 
Recent reports have highlighted the metabolic role of lungs, a highly perfused organ 
that is in direct contact with inhaled xenobiotics and drugs (Borghardt et al., 2018). 
In addition, phase I enzymes such as CYP1A1 may play an important role in 
bioactivation of inhaled procarcinogens, such as those present in tobacco smoke 
(Anttila et al., 2011). From the perspective of pharmacotherapy, pulmonary drug 
metabolism may cause a first-pass effect for inhaled medicines, as well as 
contribute to overall clearance of systemically administered drugs (Winkler et al., 
2004). Frequent exposure of the lungs to environmental xenobiotics may also lead 
to induction of drug-metabolizing enzymes via pregnane X receptors (PXR), 
constitutive androstane receptors (CAR), or aryl hydrocarbon receptors (AhR), a 
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phenomenon that can significantly alter the rate of drug metabolism (Tolson and 
Wang, 2010).  
Despite the potential importance of lung metabolism for respiratory therapies, 
relatively little is known about the actual activity and protein abundance of drug-
metabolizing enzymes in lung tissue (Hukkanen et al., 2002). The lack of 
robustness and consistency of existing experimental models of lung metabolism 
leads to considerable difficulties in the interpretation and prediction of drug 
clearance. This project was designed to address these challenges and establish a 
robust and predictive experimental model for rat and human pulmonary drug 
metabolism. Therefore the aim of this thesis was 1) to investigate the further 
development of a precision-cut lung slicing (PCLS) model to accurately estimate 
pulmonary drug clearance in rat, 2) to examine the pulmonary metabolic activity of 
rat and human phase I and phase II enzymes using this model, and 3) to compare 
the PCLS model with currently available in vitro and in vivo experimental models in 
order to better understand the contribution of pulmonary metabolism to drug 
elimination.  
1) Establish a PCLS model to accurately estimate pulmonary drug 
clearance in rat  
PCLS technology is a 3D organotypic tissue model which reflects the natural and 
relevant microanatomy and the metabolic function of the lung (Neuhaus et al., 
2017). Although the use of PCLS is becoming accepted as a research tool to 
investigate pulmonary drug metabolism, the protocols applied vary between 
laboratories and there is still opportunity to improve and standardize the 
methodology. Therefore, some of the key experimental factors used in the PCLS 
procedure were optimized with the aim of reducing variability and tissue damage 
and retaining lung metabolic activity. Due to the limited availability of fresh human 
lung tissue, method optimization was performed using rat lung tissue (under the 
assumption that rat is a suitable surrogate for human) and referring to a well-known 
CYP1A1 substrate, mavoglurant (AFQ056). The choice of mavoglurant as a test 
compound was based on two factors; 1) it is a CYP1A1 substrate and this enzyme 
is located primarily in extra-hepatic organs such as lung, kidney, brain and intestine 
(Drahushuk et al., 1998, Cheung et al., 1999, Paine et al., 1999, Smith et al., 2001) 
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and 2) metabolism of mavoglurant by CYP1A1 produces a specific metabolite, 
CBJ474, that serves as a marker for CYP1A1 metabolic activity (Walles et al., 
2013). During the optimization process of the PCLS model it was possible to 
achieve higher mavoglurant turnover by performing incubations on dynamic organ 
culture system. This investigation demonstrated the importance of optimization and 
standardization of PCLS conditions. 
2) Investigate the activity of phase I and phase II metabolic enzymes in rat 
and human lungs using PCLS model 
Preclinical species such as rats and mice are commonly used for the optimization 
of pharmacokinetic (PK) properties and for testing in vivo efficacy of new chemical 
entities. The PK data from these preclinical species is also often used for the 
prediction of human PK, and therefore, it is desirable that drug metabolism in these 
species is representative of that in human. For the comparison of enzyme activity 
in rat and human lungs, a selection of phase I and phase II probe substrates (please 
refer to chapter 3.1, Table 3 for a list of the probe substrates tested) were incubated 
using the optimized PCLS model. The results showed that there are remarkable 
differences in pulmonary metabolic activity between rat and human, reflecting 
species dependent expression of drug-metabolizing enzymes. CYP-mediated 
metabolic activity was relatively low in both species, whereas phase II enzyme 
activities appeared to be more significant in rat than in human. Therefore, care 
should be taken when extrapolating metabolism data from animal models to 
humans. 
3) Comparison of PCLS model with established in vitro and in vivo 
experimental models to be able to understand the contribution of 
pulmonary metabolism to drug elimination 
A variety of in vitro and ex vivo lung models such as cell culture, sub-cellular 
fractions, tissue slices and isolated perfused lung models have been used to 
investigate pulmonary metabolism. Each tool has advantages and disadvantages 
and can be used to answer specific scientific questions. However, due to the 
diversity of the cells in the lung it is difficult to obtain quantitative data. In this 
research project, mavoglurant and benzydamine (well-characterized FMO 
substrate) were incubated using rat lung microsomes (in vitro) and rat PCLS (ex 
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vivo) and also administered intravenously (i.v.) and intra-arterially (i.a.) to rats (in 
vivo). Previous human in vivo studies had indicated that extra-hepatic metabolism 
contributes to the elimination of mavoglurant (Novartis internal data). The goal was 
to use these models to understand if the lung makes a significant contribution to 
total body clearance. Using the well-stirred organ model, lung clearance (CLlung) of 
mavoglurant was estimated from microsomal and PCLS data and compared to the 
in vivo data obtained from i.v. and i.a. dosing to rats. The data generated from these 
three experimental models were comparable and the data suggested that the 
contribution of pulmonary metabolism to the elimination of mavoglurant is negligible. 
The same experiments were also performed using benzydamine. Interestingly, 
calculated lung clearance from microsomal data were 8-fold higher than lung 
clearance estimates from the PCLS model. Hence, similar to the PCLS-derived 
predictions, in vivo data indicated very low pulmonary clearance.  
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Chapter 2. Introduction 
The lungs are a target organ for the treatment of respiratory diseases such as 
asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and 
pulmonary infections. For the efficient and safe treatment of respiratory diseases, 
inhaled drug delivery allows the direct application of high drug concentrations to 
the target site. For inhaled drug delivery, the evaluation of local drug metabolism 
in the lung is vital in order to assess the fraction of the drug metabolized during the 
absorption process. Consequently, pulmonary drug metabolism is expected to 
exert an effect on drug bioavailability. Likewise, as lung blood flow is almost 
equivalent to cardiac output, drug metabolism may also be relevant for orally as 
well as i.v. administered drugs.  
2.1. Lung anatomy  
Through breathing, we inspire oxygenated air and the principal function of the lung 
is to distribute the oxygen to the blood and remove carbon dioxide from the body 
(Figure 1). Two separate systems deliver blood to the lungs, namely the bronchial 
and the pulmonary circulation systems (Levitzky, 2013b). The bronchial circulation 
system carries 1% of the cardiac output, nutrients and oxygen to the cells. It is 
under high pressure and a part of the general systemic circulatory system (Woo 
and Szmuszkovicz, 2009, Flieder, 2018). The pulmonary circulation system 
receives almost the entire cardiac output and carries deoxygenated blood away 
from the right ventricle of the heart in order to oxygenate the blood. It is under low 
pressure and has high flow (Lust, 2007, Sly and Collins, 2008, Culver and Glenny, 
2012, Aggarwal et al., 2015).  
The respiratory tree can be divided into a conducting zone and a respiratory zone 
as shown in Figure 2 (Levitzky, 2017). The conducting zone extends from the large 
airways to the bronchioles and terminal bronchioles and has the function of 
warming, humidifying and filtering inhaled air (Barrett et al., 2012). The respiratory 
zone includes the respiratory bronchioles, alveolar ducts, and alveolar sacs and is 
the site of gas exchange (Patwa and Shah, 2015). 
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Figure 1: Illustration of pulmonary Alveoli. (a) Clusters of alveoli and their blood supply. (b) 
Structure of an alveolus. (c) Structure of the respiratory membrane (Saladin et al., 2018)  
 
Figure 2: Conducting zone and respiratory zone of respiratory tree (Barrett et al., 2012) 
The area of the air-blood barrier where gas exchange occurs is composed of three 
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layers (Figure 1 and 3) (Horvath et al., 2015). The first layer consists of alveolar 
epithelial cells (surface area 140 m2), the middle layer is a thin basement 
membrane and the third layer is a capillary bed (surface area 130 m2) (Simionescu, 
1980). The large surface area of the air-blood barrier and its extreme thinness (0.1-
0.5 μm) facilitate rapid gas exchange by passive diffusion (Plopper, 1996). 
 
Figure 3: The air-blood barrier of the gas exchange area (Lechner and Mayo, 2015) 
The anatomical structure of the lung differs in human, dogs and common laboratory 
rodents. This may have important implications for the deposition of drug delivered 
by the inhaled route. Table 1 compares the composition of the airways and gas-
exchange barrier in human and rat lungs. During early drug discovery, new drug 
compounds are initially tested in laboratory animals. When making the translation 
of the measured lung clearance values from lab animals to human, so-called 
scaling factors are applied. These factors are species-dependent as there is 
considerable variability in metabolism across animals. Some possible reasons for 
the metabolism variability across different species are diverse enzyme isoform 
compositions, varying enzyme expression and catalytic activities, and lung 
anatomical structure differences (Tronde et al., 2003, Martignoni et al., 2006).  
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Table 1: Comparison of rat and human lung anatomical features. Data as compiled from (Crapo et 
al., 1982, Gehr, 1984, Berg et al., 1989, Levitzky, 2013a).  
 Rat Human 
Lung lobes Left lung: 1 Left lung: 2 
 Right lung: 4 Right lung: 3 
Branching Strongly monopodial, 
very sharp 
Dichotomous, 
symmetrical, sharp 
bifurcations for first 
ten generations 
 
Respiratory bronchioles Absent Several generations 
 
Structure of gas exchange barrier 
Average body weight (kg) 0.25 74 
Thickness of gas diffusion barrier (μm) 0.38 0.62 
Gas exchange surface area/unit lung volume 
(cm2/cm3) 
750 371 
Capillary volume/ unit lung volume (ml/cm3) 0.092 0.057 
 
Cellular composition in alveoli (%) 
Type I 9 8 
Type II 14 16 
Endothelial 46 30 
Interstitial 28 36 
Macrophage 3 9 
2.2. Pulmonary enzyme expression 
The lung has a unique anatomy and physiology with a highly complex architecture 
including over 40 cell types and diverse enzyme activities compared to the hepatic 
system (Nemery and Hoet, 1993, Zhang et al., 2006, Franks et al., 2008). The 
xenobiotic metabolizing enzymes are located in epithelial cells, namely in bronchial 
and bronchiolar epithelium, Clara cells, type II pneumocytes, and alveolar 
macrophages (Hukkanen et al., 2002). Numerous studies conducted on the 
metabolic activity of lung show that CYP1A1, 1B1, 2A13, 2E1, 2F1, 4B1, and 3A5 
are expressed in the lung (Zhang et al., 2006). Pulmonary enzyme expression is 
affected by a variety of genetic and environmental factors, and these enzymes play 
a very essential role as first line defense for the inhaled endogenous toxicants 
(Hukkanen et al., 2002, Castell et al., 2005). Therefore, lung may express specific 
isoforms such as e.g. UGT2A1 and CYP1A1 at a greater level than in the liver 
(Somers et al., 2007). Expression of xenobiotic-metabolizing enzymes in human 
lung are summarized in Table 2 (Zhang et al., 2006). 
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Table 2: Summary of the enzymes expressed in human lung based on literature findings (Zhang et 
al., 2006) 
Enzymes  mRNA Protein Enzymes  mRNA Protein 
Phase I 
  
Phase II 
  
1A1* +++ +++ UGTs +/- +/- 
1A2 +/- +/- SULTs + + 
1B1 ++ +/- GSTs ++ + 
2A6 ++ +/- NATs + + 
2B6 +++ +++ 
   
2C8 + +/- 
   
2D6 +/- +/- 
   
2E1 +++ +++ 
   
2J2 + ++ 
   
3A5 +++ ++ 
   
EHs ++ ++ 
   
FMOs ++ + 
   
 
+/- conflicting evidence, + weak positive evidence, ++ moderate positive evidence, +++ strong 
positive evidence, *smokers  
2.3. Contribution of pulmonary metabolism to the total body clearance of 
drugs 
Generally, if the total body clearance exceeds the liver blood flow, this can be an 
indication for extrahepatic metabolism (Kanto and Gepts, 1989). In addition to the 
fact that enzymes are expressed in lung, there are further theoretical 
considerations that pulmonary metabolism contributes to the total body clearance 
of a drug (Roth and Wiersma, 1979, Roth and Vinegar, 1990). First, the lungs 
receive almost entire cardiac output, which means that the circulating drugs or 
agents are exposed to pulmonary enzymes (Levitzky, 2013b). Furthermore, the 
lung is a first-pass metabolism organ for the drugs given by inhalation, 
intravenously, intramuscularly, subcutaneously, or topically as the drugs circulates 
first through the lung before reaching the liver (Boer, 2003). Moreover, due to the 
large vascular surface area of pulmonary veins, the compounds can circulate 
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efficiently to pulmonary enzymes (Levitzky, 2013a). The lung can be considered 
as a second-pass metabolism organ for toxic and carcinogenic metabolites as well 
(Roth and Wiersma, 1979). Consequently, pulmonary metabolism can lead to a 
decrease in the systemic availability of the drug and organ-specific toxicity (Roth 
and Wiersma, 1979, Hukkanen et al., 2002).  
2.4. Compounds metabolized by enzymes in the lung  
Several drugs including resveratrol, lidocaine, midazolam, nifedipine, nilutamide, 
phenol, theophylline, salmeterol, isoprenaline, budesonide, and ciclesonide have 
been reported to undergo significant lung metabolism (Roth and Vinegar, 1990, 
Dickinson and Taylor, 1996, Aoki et al., 2010, Joseph et al., 2013). Example of 
phase I and phase II reactions in lung are summarized in Table 3 (Cohen, 1990, 
Mutch et al., 2007, Nave et al., 2010).  
Table 3: Phase I and phase II reactions catalyzed by lung tissue 
Compound Phase I reactions Compound Phase II reactions 
Pentobarbitone Side-chain oxidation 4-Methylumbelliferone Glucuronide conjugation 
Benzo(a)pyrene Aromatic hydroxylation 3-Hydroxybenzo(a)pyrene Sulfate conjugation 
Nortriptyline N-Dealkylation 5-Hydroxytryptamine N-Methyltransferase 
N-Methylaniline N-Hydroxylation Phenol O-Methyltransferase 
Ethoxyresorufin O-Dealkylation Mercaptoethanol S-Methyltransferase 
Aldrin Epoxidation Isoprenaline Catechol O-
methyltransferase 
Nitrazepam Nitroreduction Sulfanilamide Acetylation 
Acetophenone Ketone reduction  Benz(a)anthracene 5,6-
oxide 
  
Imipramine N-oxide N-oxide reduction     
Ciclesonide Ester hydroxylation     
2.5. Compound selection 
Mavoglurant (AFQ056), a metabotropic glutamate receptor 5 (mGluR5) antagonist, 
was developed for the treatment of neurological diseases such as Fragile X 
syndrome and Parkinson’s disease (Sourial et al., 2013, Petrov et al., 2014, Berry-
Kravis et al., 2016). The full structure of mavoglurant has been shown in a previous 
publication (Walles et al., 2013). CYP1A1 efficiently catalyzes the oxidation of 
mavoglurant, leading to the formation of the metabolite CBJ474 (Walles et al., 
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2013). In addition, other substrates, such as riluzole, gefitinib, erlotinib, granisetron 
and riociguat have been shown to be partly metabolized by CYP1A1 (Sanderink et 
al., 1997, Nakamura et al., 2005, Li et al., 2007, Li et al., 2010, Khaybullina et al., 
2014). The mavoglurant clinical data indicated that extra-hepatic metabolism makes 
a significant contribution to the elimination of this compound (Novartis internal data).  
 
Benzydamine is a nonsteroidal anti-inflammatory drug (NSAID), that is marketed 
as a mouthwash solution, spray and gel for the treatment of mouth ulcers and sore 
throat (Segre and Hammarstrom, 1985, Quane et al., 1998). Benzydamine is a 
well-characterized high-turnover FMO substrate (Lang and Rettie, 2000a). Further 
examples of FMO substrates include albendazole, clindamicyn, pargyline, itopride 
and cimetidine (Rawden et al., 2000, Wynalda et al., 2003, Cruciani et al., 2014). 
FMOs catalyze the N-oxygenation of benzydamine while CYP3A4 is responsible 
for the formation of nor-benzydamine in human liver (Stormer et al., 2000). 
Benzydamine displayed high turnover in early in vitro rat lung investigations and 
there was great interest in understanding if this would translate to significant 
pulmonary clearance in vivo.  
2.5. Methods to assess lung metabolism  
Several experimental methods have been described for the investigation of 
pulmonary drug metabolism (Woods et al., 1980, Courcot et al., 2012, Costa et al., 
2014). These include cell cultures, subcellular fractions, tissue slices, isolated 
perfused lungs and whole animal models (Woods et al., 1980). The applications of 
these models and their advantages and disadvantages are summarized in Table 
4. 
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Table 4: Lung metabolism models, their applications and pros and cons  
Methods Advantages Disadvantages Field of application References 
Cultured cells  Different cell lines 
are commercially 
available, easy to 
incubate  
Enzyme abundance 
information is not 
available, difficult to 
make prediction for 
in vivo 
Metabolite 
screening, species 
comparison, 
inhibition and 
induction studies, 
drug-drug 
interaction studies 
 
(Castell et al., 
2005, Donato 
et al., 2008, 
Garcia-Canton 
et al., 2013) 
Sub-cellular 
fractions 
Easy to prepare 
and incubate, 
commercially 
available, long 
term storage is 
possible 
Lack of membrane 
transport and 
endogenic 
concurrent reactions 
to estimate the 
whole organ 
clearance process 
 
Metabolite 
screening, species 
comparison, 
inhibition and 
induction studies, 
drug-drug 
interaction studies 
(Behera et al., 
2008, 
Ioannides, 
2013) 
PCLS Intact phase I and II 
reactions, retaining 
of cell structure, 
cell contact and 
the transport 
process 
Complex 
preparation process, 
time consuming 
procedure, fresh 
tissue is needed 
Metabolite 
screening, species 
comparison, 
inhibition and 
induction studies, 
drug-drug 
interaction studies, 
toxicology studies 
 
(Price et al., 
1995, 
Umachandran 
et al., 2004, 
Pushparajah 
et al., 2007, 
Morin et al., 
2013) 
Isolated 
perfused lung 
Cells are 
maintained in their 
normal anatomical 
and physiological 
association, 
transcellular 
transport and 
diffusion of agents 
are not modified 
Time consuming, 
expensive and very 
complex procedure 
to set up the 
experiment, limited 
duration (not more 
than 8h), 
professional surgery 
is needed   
Drug ADMET 
studies 
(Niemeier, 
1984, Powley 
and Carlson, 
2002, Tronde 
et al., 2003, 
Nave et al., 
2006, Nelson 
et al., 2015, 
Bosquillon et 
al., 2017) 
 
i.v. and i.a. 
drug 
administration 
Direct in vivo 
application 
Expensive, 
technically 
challenging, require 
trained & skilled 
personal, special 
ethical approval 
needed 
 
Drug ADMET 
studies 
(Cassidy and 
Houston, 
1984, Sharan 
and Nagar, 
2013) 
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For the PCLS method the steps involved in the preparation of lung slices are 
illustrated in Figure 4. For more details on the method please refer to chapter 4.1.  
 
Figure 4: Preparation of lung tissue slices  
2.6. Hepatic elimination models 
Three models are commonly used to describe hepatic clearance: the well-stirred 
model, the parallel tube model and the dispersion model. The well-stirred model 
views the liver as a well-stirred compartment with concentration of drug in the liver 
in equilibrium with that in the emergent blood (Pang and Rowland, 1977, Yang et 
al., 2007). The parallel tube model considers the liver as a number of identical tubes, 
where each tube has plug flow of the blood carrying the drug and the metabolites 
evenly around the tubes (Ridgway et al., 2003, Poulin et al., 2012). Finally, the 
dispersion model is based on the distribution of residence times of blood elements 
within the liver (Roberts and Rowland, 1986b). All three models assume: 1) that the 
drug is distributed immediately and homogenously throughout organ water, 2) that 
the metabolizing enzymes are equally distributed through the system and 3) that 
there are no limitations to drug movement within the system (Roberts and Rowland, 
1986a, Chiba et al., 2009). However, as previously discussed, lung tissue has intact 
cells with membrane, transporters, and cell-matrix interactions. Therefore, drug 
distribution throughout the tissue is not immediate as it has to diffuse through the 
cell membrane. The transport and efflux of the drug across cell membranes may be 
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significantly affected by its physicochemical properties. Although, it is known that 
Clara cells, alveolar type I and alveolar type II cells contain drug-metabolizing 
enzymes, those cells are not homogeneously distributed in lung (Zhang et al., 
2006). Hence, all three models might have similar liabilities for lung clearance 
predictions considering the anatomical complexity and particularities of the lung. 
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Chapter 3. Results 
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Abstract 
 
Background: Although the liver is the primary organ of drug metabolism, lungs also 
contain drug-metabolizing enzymes and may therefore contribute to the elimination of the 
drugs. In this investigation, the precision-cut lung slice (PCLS) technique was standardized 
with the aims of characterizing rat and comparing rat and human pulmonary drug 
metabolizing activity. 
Method: Due to the limited availability of human lung tissue, standardization of the PCLS 
method was performed with rat lung tissue. Pulmonary enzymatic activity was found to 
vary significantly with rat age and rat strain. The dynamic organ culture (DOC) system was 
superior to well plates for tissue incubations, while oxygen supply appeared to have a 
limited impact within the 4h incubation period used here.  
Results: The metabolism of a range of phase I and phase II probe substrates was assessed 
in rat and human lung preparations. Cytochrome P450 (CYP) activity was relatively low in 
both species, whereas phase II activity appeared to be more significant.  
Conclusion: PCLS is a promising tool for the investigation of pulmonary drug metabolism. 
The data indicates that pulmonary CYP activity is relatively low and that there are 
significant differences in enzyme activity between rat and human lung. 
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1. Introduction 
 
Although the primary function of the lung is gas exchange, it also performs several 
important non-respiratory functions. Through breathing, the lung is frequently exposed to 
environmental toxicants and carcinogens and plays an important role in their detoxification. 
The same enzymes that play a role in the detoxification of these environmental components 
may also contribute to the metabolism and elimination of inhaled, orally and intravenously 
administered drugs. The awareness of pulmonary diseases such as lung cancer, bronchial 
asthma and chronic obstructive pulmonary disease (COPD) has increased during the last 
twenty years (Del Donno et al., 2002). Consequently, the inhaled route of drug delivery has 
gained more importance with the aim to treat these diseases directly. Inhaled drug delivery 
has several benefits including a small drug load with high local concentrations, immediate 
delivery of the drug to the target with a rapid onset of action and reduced systemic exposure 
and adverse reactions. If absorbed, inhaled compounds appear rapidly in the systemic 
circulation, bypassing any extensive hepatic first past effects (Rau, 2005). The lung is a 
complex organ containing over 40 different types of cells with varied functions and 
architecture (Stone et al., 1992). The location of the pulmonary metabolizing enzymes has 
been previously discussed (Zhang et al., 2006). Bronchial and bronchiolar epithelia, Clara 
cells, type II pneumocytes, and alveolar macrophages all express cytochrome P450 (CYP) 
enzymes (Devereux et al., 1989, Raunio et al., 1999). However, type I pneumocytes and 
endothelial cells, which are most directly exposed to blood flow, contain only small 
amounts of CYPs (Hukkanen et al., 2002). Phase II enzymes such as UGT1A (glucuronyl 
transferase) and GST-P1 (glutathione S-transferase), which are important detoxifying 
enzymes, are also found in lung cells (Somers et al., 2007, Olsson et al., 2011). Due to this 
diversity of cell types and variable metabolic activity, the study of pulmonary disposition 
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is challenging. Therefore, suitable in vitro tools are required to fully understand the 
potential role of pulmonary metabolism in drug disposition.  
Similar to the liver, pulmonary subcellular fractions such as microsomes and S9 are 
available from human and preclinical animal species. Although these in vitro systems 
require the addition of appropriate cofactors such as NADPH and UDPGA, they provide a 
convenient means for studying lung metabolism. Proteolytic enzymes are required for the 
preparation of subcellular fractions such as lung microsomes (Ioannides et al., 2011). 
However, these subcellular fractions lack the architecture of the intact cells and may 
therefore not fully reflect the capacity of pulmonary metabolism. Precision-cut lung slices 
(PCLS) are an alternative tool for studying lung metabolism and have several important 
advantages over subcellular fractions as they possess the full range of cell types, intact 
tissue architecture and cofactors at physiologically relevant concentrations (De Kanter et 
al., 1999, Umachandran and Ioannides, 2006). As a result, phase I and phase II metabolic 
processes are fully represented by tissue slices (Ioannides et al., 2011). The use of rat PCLS 
for drug metabolism investigations was first reported in 1977 (O'Neil et al., 1977). As an 
example, in vitro human pulmonary metabolism of ciclesonide, an inhaled corticosteroid, 
was investigated using PCLS (Nave et al., 2006). Furthermore, PCLS have recently been 
used to study the metabolism of mavoglurant (Yilmaz et al., 2017).  
One drawback of the PCLS model is that it generally requires fresh tissue. Although this is 
routinely available for rodent species, its availability is limited for human and other species 
such as dog and monkey. Nevertheless, the use of PCLS show great promise as the 
methodology can be easily applied to different organs such as liver, kidney and brain and 
may also be used to identify potential differences in drug metabolism between human and 
animals used for toxicological studies (De Kanter et al., 2002). Lung slices can be produced 
from limited amounts of tissue and, therefore, surgical waste material may be suitable for 
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this purpose (Kanter et al., 2002). The preparation of subcellular fractions from similar 
amounts of tissue would typically result in poor yields of protein. Although lung 
microsomes and S9 are commercially available and relatively inexpensive, their 
preparation time is usually longer than that of tissue slices, potentially leading to loss of 
metabolic activity. Furthermore, enzymatic activity will be adversely affected by repeated 
freeze-thaw cycles and this should be avoided when using microsomes and S9. In recent 
years, the potential use of tissue cryopreservation has been investigated to reduce the 
dependence of the PCLS model on fresh material (de Graaf and Koster, 2003). Yet, a robust 
methodology for tissue cryopreservation has so far not been developed and, therefore, has 
not been used in the current investigations.  
Although lung slicing technology is commonly used in metabolism studies, the protocols 
used vary between laboratories and there is still opportunity to improve and standardize the 
technique (Liberati et al., 2010). Therefore, in this study, some of the key experimental 
factors used in the PCLS procedure were optimised with the aim of reducing tissue damage 
and retaining lung metabolic activity. The PCLS incubation conditions were partly 
optimised and fully standardized using the CYP1A1 substrate, AFQ056. CYP1A1 has 
previously been shown to efficiently catalyse the oxidation of AFQ056, leading to the 
formation of the metabolite, CBJ474 (Walles et al., 2013). CYP1A1 is widely recognised 
as an extrahepatic enzyme that is expressed in organs including kidney, intestine and lung 
(Ding and Kaminsky, 2003, Nishimura and Naito, 2006, Bieche et al., 2007). CYP1A1 
mRNA is known to have a short half-life of approximately 2.4 h (Lekas et al., 2000) and it 
is therefore critical that the experimental conditions used do not adversely affect CYP1A1 
activity. The pulmonary metabolism of AFQ056 is sensitive regarding the conditions used 
and was therefore considered to be suitable for the optimization of the PCLS conditions. 
Finally, the optimised and standardized PCLS parameters were used to compare rat and 
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human pulmonary enzyme activity. Incubations were performed with a range of substrates 
for enzymes including CYPs, FMOs, UGTs and SULTs and were selected based upon 
literature data, availability of reference standards for parent compound and metabolite 
quantification. 
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2. Materials and Methods 
 
2.1. Reagents, chemicals, and materials 
AFQ056 (mavoglurant) and NVP-CBJ474 (AFQ056-M3) were synthesized at Novartis 
(Basel, Switzerland). Minimal Essential Medium (MEM, without L-glutamine, HEPES, 
and phenol red) and agarose UltraPure™ low melting point were purchased from Life 
Technologies (Carlsbad, CA). 4-Methylumbelliferone, 4-methylumbelliferyl glucuronide, 
4-methylumbelliferyl sulfate, benzydamine, ramipril, triclosan, carbazeran, diclofenac, 
diazepam, amodiaquine, sumatriptan, P-toluidine and 4-methylacetanilide were purchased 
from Sigma Aldrich. Benzydamine N-oxide, ramiprilat, triclosan glucuronide, triclosan 
sulfate, 4-hydroxycarbazeran, 4-hydroxydiclofenac, diclofenac glucuronide, midazolam, 1-
hydroxymidazolam, nordiazepam and N-desethylamodiaquine were purchased from 
Toronto research chemicals. 
2.2. Standardization of the PCLS incubation conditions 
Rat lung tissue slices were performed as previously described (Yilmaz et al., 2017). The 
impact of animal age was investigated by performing incubations with lung slices from 
Sprague Dawley (SD) rats aged between 6 and 12 weeks. In order to evaluate differences 
in enzyme activity due to rat strain, lung tissue was also obtained from 6 week old Wistar 
Han (WH) rats. PCLS incubations were performed using titanium (type C) roller inserts 
(Vitron Inc., Tucson, AZ). Three lung tissue slices (average weight 0.024 g/slice) were 
positioned onto the roller inserts and then placed in glass vials (Figure 1). The glass vials 
were prefilled with a modified dynamic organ culture medium composed of MEM, HEPES 
(25mM) and glucose (25 mM) (Smith et al., 1985, Smith et al., 1986).  
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Table 1: Important parameters for the tissue slice preparation 
Factors Subfactors Comments 
Animals Strains Sprague Dawley & Wistar Han 
 Age 6-12 weeks 
 Fed/fasted Fed 
Anesthesia Drug 3-5% Isofluran 
 Duration 3 min 
Slice preparation Agarose gel  Low melting point (2.5% v/v) 
 Slice thickness /weight ~416 µm / ~24 mg 
 Buffer MEM, HEPES, Glucose 
Medium Volume 2mL 
 Rotating frequency 4 rpm 
Incubation 
conditions 
Temperature 37 °C 
 Duration of incubation 0-4 h 
 Incubation system Dynamic organ culture system & 
well-plate 
These factors should be considered to minimize tissue damage in order to obtain an accurate 
and reproducible system for the determination of pulmonary drug metabolism. 
During the optimization process, the DOC incubation system was compared with well-
plates (Figure 2) to determine if the pulmonary activity was dependent upon the incubation 
device. As the primary role of the lung is gas exchange, the impact of the oxygen content 
in the incubation system on drug metabolism was investigated. For that, metabolic activities 
were compared using an oxygen rich atmosphere (75% O2, 5% CO2) and an atmosphere 
composed of 5% CO2 and normal air (21% O2 content). 
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Figure 1: Incubation vial for dynamic organ culture system 
For PCLS incubations three lung tissue slices (average weight 0.024 g/slice) were 
positioned onto the titanium (type C) roller inserts and then placed into glass vials. The 
glass vials were filled with a modified medium composed of MEM, HEPES (25mM), 
glucose (25 mM) and compounds of interest. Each time point was carried out in duplicate 
comprising 3 slices for each time point, and each incubation was carried out in triplicate.  
 
Figure 2: Precision cut lung slices incubation on well plate system  
For PCLS incubations 12 well-plates were filled with 2 mL of a medium composed of 
MEM, HEPES (25mM), glucose (25 mM) and compounds of interest. On each plate, three 
lung tissue slices (average weight 0.024 g/slice) were positioned and incubated for 4h.  
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2.3. Preparation and incubation of lung tissue slices  
Animal experiments were conducted with the approval of the Cantonal Veterinary 
Authority of Basel City, Switzerland (Protocol BS-2723). Male SD and WH rats, with an 
average age of 6 – 12 weeks and body weight of 200 – 250 g, were used in this study 
(Charles River Germany). Fresh rat lungs were obtained with the trachea and immediately 
put on ice after surgery until processing.  
The use of human lung tissue was approved by the local ethics committee of Basel, 
Switzerland (EKNZ 2015-355) and the studies were performed in accordance with the 
Declaration of Helsinki (1964 and subsequent revisions). In written manner the informed 
consent was obtained from the study participants. Tumour-free tissue samples from 
different region of the lung were collected post-surgically from six patients at the 
Department of Thoracic Surgery, University Hospital Basel. Basic demographic 
information is presented in Table 2. The excised lung samples were immediately 
submerged in cold MEM medium. Samples were transported to our laboratories at 4 ºC 
within 60 min from the time of surgical excision.  
Table 2: Demographic information of human lung donors 
Donor Gender Ethnicity Primary lung disease 
1 Male Caucasian Bronchiectasis 
2 Female Caucasian Lung cancer 
3 Male Caucasian Lung cancer 
4 Male Caucasian Lung cancer 
5 Male Caucasian Lung cancer 
6 Male Caucasian Lung cancer 
Macroscopically healthy lung tissue surrounding the tumor or lesion was collected post-
surgically from subjects aged 45 – 79 years.  
Pre-warmed lung tissue (37 °C for 5 min) was inflated with a 37 °C solution of agarose 
(low melting point, 2.5% v/v) in MEM medium. The rat lungs were inflated via the trachea, 
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whereas human lung tissue was inflated by injecting airways using a syringe and needle. 
The preparation of lung slices and 4h incubations were performed as previously described 
(Yilmaz et al., 2017). An important consideration is the slice thickness that the cut surface 
of the slice contains mainly damaged cells and if the slice thickness decreases then the 
overall slice metabolism can be affected. Furthermore, if the slice thickness increases this 
can lead to suboptimal metabolism due to the substrate delivery and gas diffusion difficulty 
(Liberati et al., 2010). Slice thickness (~416 µm) was chosen in this case based on the 
previous findings (O'Neil et al., 1977, Dogterom, 1993, Liberati et al., 2010, Sanderson, 
2011). The incubation reactions were stopped after 4 h by addition of 3 mL of acetonitrile. 
The samples were vortex mixed and stored at -80 °C until further processing.  
For the enzyme activity comparison between human and rat lungs, numerous phase I and 
phase II enzyme substrates (listed in Table 3) were incubated and substrate concentration 
as well as metabolite formation were measured. The monitored metabolites are also shown 
in Table 3. Probe substrates for drug-metabolizing enzymes were selected based on 
literature reports of the specific biotransformation pathways and enzymes involved and 
availability of synthetic standards enabling quantification of formed metabolites. 4-
Methylumbelliferone and triclosan have been described as broad substrates for human 
UGTs and mammalian SULTs (Wang et al., 2004, Manevski et al., 2013). P-Toluidine was 
reported to be a substrate for human N-acetyltransferases present in human skin (Gotz et 
al., 2012, Manevski et al., 2015). Midazolam hydroxylation to 1’-hydroxymidazolam is 
catalysed by human CYP3A4/3A5 (Yuan et al., 2002). Amodiaquine N-deethylation is 
catalysed by CYP2C8 leading to the formation of N-desethylamodiaquine (Li et al., 2002). 
Diclofenac hydroxylation to 4’-hydroxydiclofenac is catalysed by human CYP2C9 (Carlile 
et al., 1999). Diazepam N-demethylation to nordiazepam is predominantly catalysed by 
human CYP2C19 and CYP3A (Ono et al., 1996). Benzydamine is reported to be a high-
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turnover substrate for human FMOs (Lang and Rettie, 2000b) and carbazeran 
hydroxylation to 4-hydroxycarbazeran is catalysed by human aldehyde oxidase (Kaye et 
al., 1985, Hutzler et al., 2012). Rampril hydrolysis to ramiprilat was reported to be 
catalyzed by human carboxyl esterase 1 (CES1) (Thomsen et al., 2014).  
2.4. Analytical methods  
Samples were quantitatively analysed using a Triple Quadripole 6500 LC-MS/MS system 
(AB Sciex, Ontario, CA) coupled to a UPLC system (Waters Acquity). Separations were 
achieved using various reversed phase stationary phases. The analytical columns and 
mobile phase compositions were developed for the simultaneous quantification of substrate 
and metabolite and are summarised in Table 4. This analytical methods are developed based 
on the literature findings and for this research purpose. The columns were operated at 40 
°C, and eluted with a mobile phase flow rate of 400 µL/min. The presence of metabolites 
were confirmed by chromatography with reference standards.  
Table 3: Probe substrates and corresponding metabolites used to investigate pulmonary 
metabolism 
Compound Metabolic reaction Metabolite Responsible enzyme  
Triclosan Glucuronidation Triclosan glucuronide UGT 
Triclosan Sulfation Triclosan sulfate  SULTs 
4-MU Glucuronidation 4-MUG UGT 
4-MU Sulfation 4-MU-Sulfate  SULTs 
P-Toluidine N-Acetylation 4'-Methylacetanilide NATs 
Midazolam Hydroxylation 1-Hydroxymidazolam  CYP3A4 
Amodiaquine N-deethylation N-Desethylamodiaquine  CYP2C8 
Diclofenac Hydroxylation 4-Hydroxydiclofenac CYP2C9 
Diazepam N-demethylation Nordiazepam CYP2C19/3A 
AFQ056 4-hydroxylation CBJ474 CYP1A1 
Benzydamine N-Oxygenation Benzydamine-N-oxide FMOs 
Carbazeran  Hydroxylation 4-Hydroxycarbazeran AO 
Ramipril Hydrolysis Ramiprilat CES1 
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The probe substrates used in this study, their respective metabolites and responsible 
enzymes are shown. 
Prior to analysis, samples were prepared as follows. The samples were thawed and 
sonicated for 5 min and 200µL aliquots were transferred to a new tube containing 400 µL 
acetonitrile with internal standard, estradiol glucuronide. The diluted samples were vortex 
mixed and sonicated for 2 min and then centrifuged for 15 min at 15000 g. The supernatants 
were transferred to a new tube and evaporated to dryness under a stream of nitrogen. 
Finally, the samples were reconstituted in 150µL 95/5 (v/v) water/acetonitrile containing 
0.1 % formic acid and analysed by LC-MS/MS. The LLQ for the metabolites were 0.001 
µM. 
 
 
 .  
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Table 4: LC-MS/MS methods for the determination of probe substrates and metabolites 
Analyte Column SRM transition Gradient A 
Gradient 
B 
Gradient 
profile  
Ionization 
mode 
AFQ056 
Kinetex C8, 2.6 µm, 2.1x50 mm 
296/221 
0.1% FA in H2O ACN A ESI + 
CBJ474 312/237 
4-MU 
Phenomenex Luna Phenylhexyl, 3 µm, 
2.0x150 mm 
175/133 
20 mM NH4HCO2 (pH 4.2) in H2O MeOH B ESI - 4-MU glucuronide 351/175 
4-MU sulfate  255/175 
Benzydamine 
Supelco Ascentis C18, 3 µm, 2.1x50 mm 
310/265 
20 mM NH4HCO2 (pH 4.2) in H2O ACN A ESI + 
Benzydamine-N-oxide 326/102 
Ramipril 
Supelco Ascentis C18, 3 µm, 2.1x50 mm 
417/234 
20 mM NH4HCO2 (pH 4.2) in H2O ACN A ESI + 
Ramiprilat 389/156 
Triclosan 
Supelco Ascentis C18, 3µm, 2.1x50 mm 
289/289 
287/287 
0.1% FA in H2O ACN B ESI - Triclosan glucuronide 463/287 
Triclosan sulfate  
367/175, 
367/287 
Carbazeran  
Supelco Ascentis C18, 3 µm, 2.1x50 mm 
361/272 
0.1% FA in H2O ACN A ESI + 
4-Hydroxycarbazeran 377/288 
Diclofenac 
HALO C18, 3 µm, 2.1x100mm + guard 
294/250, 
294/214, 
296/252 
0.1% FA in H2O ACN A ESI - 
4-Hydroxydiclofenac 
310/266,  
312/268, 
312/232 
Diclofenac glucuronide 
470/193, 
470/250, 
470/175, 
472/193 
Midazolam 
Supelco Ascentis C18, 3 µm, 2.1x50 mm 
326/291 
20 mM NH4HCO2 (pH 4.2) in H2O ACN A ESI + 
1-Hydroxymidazolam  342/324 
Diazepam 
Supelco Ascentis C18, 3 µm, 2.1x50 mm 
285/193 
20 mM NH4HCO2 (pH 4.2) in H2O ACN A ESI + 
Nordiazepam 271/208 
Amodiaquine 
Supelco Ascentis C18, 3 µm, 2.1x50 mm 
356/283 
0.1% FA in H2O ACN C ESI + 
N-Desethylamodiaquine  328/283 
P-Toluidine Phenomenex Luna Phenylhexyl, 3 µm, 
2.0x150 mm 
108/93 
0.1% FA in H2O  ACN A ESI + 
4'-Methylacetanilide 150/108 
Estradiol Glucuronide (IS)  447/271     
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Gradient elution profiles 
A= 0-1 min 5% B, 5 min 50% B, 10-11 min 95% B, 12-15 min 5% B 
B= 0-1 min 5% B, 5 min 30% B, 6-12 min 95% B, 12.5-15 min 5% B 
C= 0-1 min 5% B, 6 min 80% B, 10-13 min 95% B, 13.5-15 min 5% B 
 
Chapter 3. Results | 45 
3. Results 
 
3.1 Standardization of the PCLS assay conditions  
The initial aim of this investigation was the standardization of the PCLS incubation conditions. 
As mentioned earlier, some of the important incubation conditions were optimized using the 
CYP1A1 substrate, AFQ056. Furthermore, due to the limited availability of fresh human lung 
tissue, the optimization process was carried out using rat tissue with the assumption that rat 
lung is a suitable surrogate for human lung. 
The PCLS results indicated that pulmonary CYP1A1 activity varied with rat age and rat strain 
(Figure 3). AFQ056 turnover was approximately 1.5-fold higher in 6 week than in 12 week old 
SD rats. Similarly, pulmonary CYP1A1 activity in 6 week old SD rats was approximately 1.8-
fold higher than in WH rats of the same age (Figure 3).  
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Figure 3: Age and strain dependent lung metabolism of AFQ056 in rats 
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AFQ056 (1 µM) was incubated for 4h with lung tissue slices obtained from 6 and 12 week old 
SD rats and 6 week old WH rats. The metabolite, CBJ474 formed after 4 h was quantified and 
expressed as a percentage of initial AFQ056. Data are presented as mean values ± S.D. (n=3). 
Each time point was carried out in duplicate comprising 3 slices for each time point, and each 
incubation was carried out in triplicate. The kinetic experiments showed linear formation of 
CBJ474 with time as shown in the previous investigations (Yilmaz et al., 2017) (Figure 4B). 
The choice of the incubation vessel was also found to be an important consideration when 
performing PCLS incubations. As shown in Figure 4, a higher CBJ474 formation was observed 
with the DOC incubation system than with the well plates. Although the use of the rollers was 
more cumbersome than a simple well plate, it is evident that they plaid a crucial role in 
obtaining optimum enzymatic activity.  
Given that the in vivo, the lungs are directly exposed to the atmosphere, the influence of the 
oxygen content in the incubation buffer was investigated. The results indicated that CYP1A1 
activity was not influenced by the atmospheric oxygen content during the 4h incubation period 
used here (Figure 4). This insensitivity to the oxygen content may have been due to the fact 
that the incubation buffer was routinely saturated with oxygen prior to starting the incubation. 
The addition of this amount of oxygen may have been sufficient to support enzyme activity 
during the 4 h incubation period. 
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Figure 4: The impact of the incubation system on AFQ056 pulmonary metabolism  
AFQ056 (1 µM) was incubated for 4h with lung tissue slices obtained from 6 week old SD 
rats. The impact of oxygen supply on CBJ474 formation was investigated. Dynamic organ 
culture (DOC) and well plate incubation systems were also compared. The metabolite, 
CBJ474, formed after 4 h was quantified and expressed as a percentage of initial AFQ056. 
Data are presented as mean values ± S.D. (n=3). Each time point was carried out in duplicate 
comprising 3 slices for each time point, and each incubation was carried out in triplicate.  
3.2. Comparison of pulmonary enzyme activity in rats and humans 
The pulmonary metabolism of a selection of phase I and II substrates in rat and human lung 
tissue was compared using the optimum conditions discussed above. The results suggested that 
there were considerable species differences with respect to the metabolism of the probe 
substrates tested (Figure 5). Although CYP activity was generally low in both species, activity 
in human lung appeared to be remarkably lower than in rat. Accordingly, with the exception 
of CBJ474, it was not possible to detect the CYP mediated metabolites in human lung 
incubations. The formation of CBJ474 is mediated by CYP1A1 (Yilmaz et al., 2017), an 
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isoform that is thought to be expressed in extrahepatic tissues including the lung. The data 
shown here demonstrates the presence of CYP1A1 in lung tissue albeit to a lesser extent in 
human than in rat.  
Similarly, remarkable benzydamine N-oxygenation was observed in rat lung, whereas activity 
in human lung was negligible (approximately 1 % of initial parent concentration during 4 h). 
The limited carbazeran hydroxylation observed in both species suggested that pulmonary 
aldehyde oxidase activity is low irrespective of the species.  
T
r i
c
lo
s
a
n
 (
U
G
T
s
)
T
r i
c
lo
s
a
n
 (
S
U
L
T
s
)
4
-M
U
 (
U
G
T
s
)
4
-M
U
 (
S
U
L
T
s
)
P
-T
o
lu
id
in
e
 (
N
A
T
s
)
M
id
a
z
o
la
m
 (
C
Y
P
3
A
4
)
A
m
o
d
ia
q
u
in
e
 (
C
Y
P
2
C
8
)
D
ic
lo
fe
n
a
c
 (
C
Y
P
2
C
9
)
D
ia
z
e
p
a
m
 (
C
Y
P
2
C
1
9
/3
A
)
A
F
Q
0
5
6
 (
C
Y
P
1
A
1
)
B
e
n
z
y
d
a
m
in
e
 (
F
M
O
s
)
C
a
rb
a
z
e
ra
n
 (
A
O
)
R
a
m
ip
r i
l 
(C
E
S
1
)
0 .1
1
1 0
1 0 0
M
e
ta
b
o
li
te
 f
o
rm
a
ti
o
n
 (
%
)
R at
H um an
 
Figure 5: Comparison of rat and human pulmonary drug metabolizing activity  
Chapter 3. Results | 49 
Substrates (1 µM) were incubated in the presence of rat and human lung PCLS for 4 h. The 
metabolites were quantified and are displayed as a percentage of initial substrate concentration. 
Data are presented as mean values ± S.D. (n=3). Each time point was carried out in duplicate 
comprising 3 slices for each time point, and each incubation was carried out in triplicate. 
In contrast to the generally low oxidative metabolism observed here, pulmonary phase II 
processes appeared to be prominent. Triclosan and 4-MU underwent sulfation in rat and human 
lung with comparable turnover displayed in both species. Furthermore, toluidine N-acetylation 
also occurred in both species to a similar extent. Although glucuronidation of the UGT 
substrates, triclosan and 4-MU was observed in both rat and human lung, the velocity was 
significantly higher in rat than in human lung. CES1 mediated hydrolysis of ramipiril was 
comparable in rat and human lung slices. 
50 | Chapter 3. Results 
4. Discussion 
 
Although the liver has the highest metabolic capacity of all organs, the lung could also 
contribute to the total body clearance of drugs. The fact that the lungs receive 100% of the 
cardiac output, which means that the whole quantity of circulating compounds is exposed to 
pulmonary enzymes, may be a reason why lungs could contribute to total body drug clearance. 
Consequently, every compound given intravenously, intramuscularly, subcutaneously or 
topically circulates through the lung before reaching the liver. Therefore, the metabolic first-
pass of the lung could be significant for drug applications bypassing intestinal absorption. 
PCLS provide a great possibility to investigate in vitro pulmonary drug metabolism using fresh 
rat or human lung tissue. Since the slices contain all relevant cell and metabolite components, 
the results obtained in vitro could predict the in vivo pulmonary metabolism of specific drugs. 
Although the successful use of PCLS for drug metabolism studies has previously been 
demonstrated (Nave et al., 2006), there is a still a need to evaluate and improve the protocols 
used with the aim to optimize this technique. Herein, the impact of several key factors 
including rat age and rat strain, incubation vessels and oxygen supply were evaluated (Table 
1).  
As shown in Figure 3, differences in CBJ474 formation were observed between 6 and 12 week 
old SD rats. These observations are consistent with the fact that in the rat, age-related changes 
in anatomy, morphology, biochemistry, and physiology are known to result in corresponding 
changes in drug metabolizing activity (Nijjar and Ho, 1980, Van Bezooijen et al., 1986, 
Yamamoto et al., 2003, McCutcheon and Marinelli, 2009, Samuel et al., 2016, Bozhkov et al., 
2017). The age of a rat can be defined in three specific life phases: infants (<3 week), juveniles 
Chapter 3. Results | 51 
(3-8 weeks), and adults (from 8 weeks up to 1.5 years). It appears that juvenile rats have higher 
pulmonary CYP1A1 activities than adult rats. Similarly, differences in CYP1A1 mRNA 
expression and metabolic activity among rat strains have previously reported (Nishiyama et 
al., 2016). The impact of this strain-dependent CYP1A1 activity can be seen in Figure 3, where 
CBJ474 formation is shown to be greater in 6 week old SD than in WH rats of the same age. 
Given the age and strain differences in metabolic activity observed here, it is important that 
age and strain of animals used in this type of metabolic studies are standardised to obtain 
comparable results with a low variability. We therefore recommend that 6 week old juvenile 
SD rats are used wherever possible. 
The choice of the incubation vessel was also found to be important as higher CBJ474 turnover 
was seen with the DOC system than with multi-well plates. The continuous rotation of the 
titanium rollers in the DOC system may result in more efficient oxygenation and optimal 
substrate and nutrient delivery to the tissue slices, therefore mimicking the in vivo situation 
more closely (Fisher et al., 1995, Parrish et al., 1995, Umachandran et al., 2004, Umachandran 
and Ioannides, 2006, Morin et al., 2013). The primary drawback of the DOC system is that the 
number of incubations that can be performed in parallel is limited and that a specific incubator 
has to be purchased. Incubations could be more efficiently performed using multi-well plates, 
which allow increasing the number of incubations much more easily. However, as shown in 
this study, the metabolic activity is compromised when well plates are used (Figure 4). 
Although the influence of oxygen supply on lung slice viability has been reported previously 
(Siminski et al., 1992, Monteil et al., 1999), our data suggests that oxygen supply has an only 
limited impact when incubation times are short (4h) and the buffer is pre-oxygenated. Based 
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on these results, subsequent incubations were performed using the DOC system at atmospheric 
oxygen tension and buffer pre-oxygenation. 
The optimization process discussed here was performed with a single compound, AFQ056, a 
CYP1A1 substrate. While this may be considered to be a limitation, the well documented 
fragility of CYP1A1 (Lekas et al., 2000) requires additional care to maintain the activity when 
performing PCLS experiments. The data shown here are consistent with previous results 
(Yilmaz et al., 2017), reflecting the reproducibility of our procedure. We consider therefore 
AFQ056 a suitable compound for monitoring the performance of the PCLS procedure. 
The use of human tissue in this study turned out to be difficult but nevertheless yielded valuable 
results. The preparation of human tissue slices was technically more challenging than rat slices 
and, therefore, appropriate modifications of the methodology had to be made. Rat lungs could 
easily be inflated with agarose via the intact trachea. However, human lung tissue was obtained 
as surgical waste, and airways were generally not visible. Human tissue was therefore carefully 
inflated via a series of small injections of agarose gel using a fine needle. Care was taken to 
avoid applying excessive pressure that could have caused bursting of alveoli, possibly leading 
to loss of metabolic activity. It is therefore possible that not only species differences, but also 
the quality of the lung slices has contributed to the lower enzyme activities in human compared 
to rat lung. 
We were fortunate to obtain fresh human lung tissue from the local University Hospital. 
Although the availability of human tissue was limited, we aimed to reduce experimental bias 
by processing the human tissue samples as carefully and rapidly as possible. It can be assumed 
that the health status of the subjects had only a limited impact on the results as the tissue 
collected was not tumorous. The PCLS technique is dependent upon the availability of fresh 
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tissue and, therefore, samples were transported from the hospital to our laboratory within one 
hour of isolation. Tissue slices were then quickly prepared within 90 minutes to minimise any 
loss of metabolic activity. 
In the past years various studies have been published on the characterization, expression levels 
and localization of xenobiotic metabolizing enzymes in the lung, but information about the 
functional aspects of these enzymes is rare (Lorenz et al., 1984, Pacifici et al., 1988, Zhang et 
al., 2006). Possible reasons for this information gap may be that the activity of drug-
metabolizing enzymes in lung tissue is low (in particular regarding phase I metabolism 
enzymes) and that suitable systems for long-term measurement of enzyme activities have not 
been available. PCLS may close this gap. The data of the current investigation shows that phase 
II activity in rat and human lung is reasonably comparable and that the activity of phase II is 
considerably higher than of phase I enzymes (Figure 5). This is consistent with previously 
published data that summarised the expression and activity of drug-metabolizing enzymes in 
human lung (Somers et al., 2007).  
Pulmonary UGT activity was assessed using the non-selective UGT substrates, triclosan and 
4-MU. Although UGT activity appeared to be higher in rat than in human lung, this finding 
has to be interpreted with caution, since the metabolism of triclosan and 4-MU depends not on 
the activity of one specific UGT, but on the interplay of different UGT isoforms present in the 
lungs of these two species (Uchaipichat et al., 2004, Jackson et al., 2013).  
While pulmonary CYP450 activity was low in both species, the activity in human lung 
appeared to be even lower than in rat lung. The low pulmonary CYP450 activity observed here 
is in clear contrast to the role of this enzyme family in the liver. Regarding Flavin mono-
oxygenases, remarkably greater benzydamine N-oxygenation activity was observed in rat than 
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in human lung. The pronounced N-oxide formation observed here in rat is consistent with 
previously obtained data (Yilmaz et al., 2018). FMOs are known to display complex species, 
tissue and gender dependent expression, which may account for the species difference 
observed here (Ripp et al., 1999, Janmohamed et al., 2004, Hines, 2006, Phillips and Shephard, 
2017). FMO expression in human lung is low and the major pulmonary isoform, FMO2 is 
catalytically inactive in Caucasians (Dolphin et al., 1998, Cashman and Zhang, 2006). As this 
study only included lung tissue from Caucasian donors, it is not surprising that limited N-oxide 
formation was observed. It would be interesting to explore pulmonary FMO activity from other 
populations, such as native Africans, where active FMO2 is expressed in lung (Cashman and 
Zhang, 2006). Aldehyde oxidase mediated oxidation of carbazeran was observed to a limited 
extent in both species. Aldehyde oxidase has been shown to be expressed in the bronchial 
epithelium of rats (Garattini et al., 2009). The role of aldehyde oxidase in extrahepatic 
metabolism has so far not been fully explored and further investigations would be of interest. 
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5. Conclusion  
 
Due to time constraints, only key experimental parameters were evaluated during our 
optimization of the PCLS technique. The study demonstrates the importance of optimization 
and standardization of PCLS conditions, eventually resulting in a more reliable method to 
determine pulmonary metabolic activity. The reason for our particular interest in the 
comparison of pulmonary enzymatic activity in rats and humans is that animal models are 
commonly used in the preclinical development of new drugs. The results show that there are 
remarkable differences in pulmonary metabolic activity between rats and humans, reflecting 
species and tissue dependent expression of drug-metabolizing enzymes. Care should therefore 
be taken when extrapolating metabolism data from animal models to humans. PCLS turned 
out to be a valuable tool for the investigation of pulmonary drug metabolism and should be 
developed further for assessing enzyme and metabolic activities not only in lungs but also in 
other organs. 
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List of Abbreviations  
PCLS   = Precision-cut lung slices  
DOC  = Dynamic organ culture  
CYP   = Cytochrome P450  
COPD  =  Chronic obstructive pulmonary disease 
UGTs  = UDP-glucuronosyltransferase  
GST  = Glutathione S-transferase 
SULTs  = Sulfotransferases 
NADPH = Nicotinamide adenine dinucleotide phosphate   
UDPGA = Uridine-diphosphate-glucuronic acid trisodium salt  
FMOs  =  Flavin-containing monooxygenase 
SD  = Sprague Dawley 
WH  = Wistar Han  
MEM  = Minimal Essential Medium  
UPLC  = Ultra Performance Liquid Chromatography  
LLQ  = Lower Limit of Quantitation  
4-MU  = 4-Methylumbelliferone 
CES1  = Carboxylesterase 1 
AO  = Aldehyde oxidase 
S.D.  = Standard deviation 
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Chapter 4. Discussion and outlook 
In recent years, the use of PCLS has increased for industrial applications such as 
testing of chemicals and xenobiotics as it offers advantages over cell-lines and 
subcellular fractions (as discussed in chapter 4). In addition to drug metabolism, PCLS 
is used for toxicology and biomarker studies (Lauenstein et al., 2014, Hess et al., 2016, 
Hesse et al., 2016). PCLS model facilitates the investigation of drug metabolism, as 
the method is applicable to healthy and diseased lung tissue from different species by 
retaining both anatomical and physiological conditions. Another advantage of 
precision-cut tissue slicing is that hepatic and extra-hepatic drug-metabolizing 
enzymes can be induced by this technique (Price et al., 2004).  
4.1. Optimization of the PCLS model for more accurate estimation of pulmonary 
drug clearance 
In order to optimize the PCLS model, different incubation conditions were tested and it 
was possible to achieve higher turnover using a dynamic organ culture system. Oxygen 
supply appeared to have negligible effect on metabolic turnover in incubations of 4 h 
duration. However, oxygen supply might be an essential parameter for incubations of 
longer duration in order to maintain the slice viability. This work clearly showed the 
importance of optimization and standardization of PCLS conditions for the metabolism 
studies. However, supplementary experiments using a broader range of probe 
substrates could be of interest to further evaluate the PCLS model. The in-house 
application of the PCLS model may also be extended to toxicology investigations. 
4.2. Comparison of phase I and phase II metabolic activity in rat and human lungs 
This study demonstrated that there are significant differences in pulmonary enzyme 
activity between rats and humans, which is due to the species and tissue dependent 
expression of these enzymes. Our results indicate that phase II activity appears to be 
more prevalent in rat than in human lung and that phase II activity is considerably 
higher than that of phase I enzymes. This work highlights the differences in pulmonary 
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metabolic activity between rat and human and emphasizes the importance of critically 
evaluating data derived from animal models. In order to answer the question: to what 
extend does lung metabolism in rat reflects the situation in the human lung, yet 
extensive research will be required for a statistical analysis using a broader range of 
specific probe substrates. 
4.3. Comparison of PCLS, in vitro and in vivo experimental models for the 
investigation of pulmonary contribution to drug metabolic clearance 
4.3.1. Mavoglurant and CYP1A1 
Experiments were performed to determine if pulmonary metabolism contributed to the 
total body elimination of mavoglurant. Our data suggests that the lungs make a 
negligible contribution to mavoglurant elimination in rat. It remains unclear which other 
organs may contribute to the total body clearance of this compound. Previous 
investigations regarding mavoglurant CYP1A1-mediated elimination by kidney 
demonstrated negligible contribution (Novartis internal data). The contribution of brain 
and intestinal CYP1A1 to the metabolism of mavoglurant should be further 
investigated. 
Although there was conflicting evidence for the expression of CYP1A1 protein in liver, 
current studies indicate that CYP1A1 expression in human liver is low. (Drahushuk et 
al., 1998, Nakamura et al., 2005). CYP1A1 is regulated by the AhR and is highly 
inducible by some PAHs, such as those found in cigarette smoke (Nebert et al., 2004, 
Elsherbiny and Brocks, 2011, Klingbeil et al., 2014, Moorthy et al., 2015, Wohak et al., 
2016). The results of a clinical study (Novartis internal data) showed that mavoglurant 
Cmax and AUCinf in smokers were reduced by 41% and 46%, respectively, compared 
to nonsmokers. These results indicate that smoking induces CYP1A1 expression in 
the body and consequently reduces systemic exposure of mavoglurant. Therefore, the 
potential of CYP1A1 induction should not be underestimated. It is speculated that once 
the induction is initiated, CYP1A1 becomes highly efficient in all organs such as lung, 
brain, kidney, intestine and liver (van de Kerkhof et al., 2008, Walsh et al., 2013). 
Therefore, following CYP1A1 induction the level of hepatic and extrahepatic 
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metabolism can be significantly altered.  
Likewise, for other CYP1A1 substrates such as riluzole, gefitinib, erlotinib, granisetron 
and riociguat, marked differences in systemic exposure have been reported in smokers 
and non-smokers. (Sanderink et al., 1997, Corrigan et al., 1999, Nakamura et al., 2005, 
Li et al., 2007, Li et al., 2010, Khaybullina et al., 2014, Frey et al., 2016, Saleh et al., 
2016). These findings support the assumptions described above. Therefore, further 
investigations using the tissue slice model following CYP1A1 induction could 
potentially help to understand the importance of hepatic and extra-hepatic CYP1A1 
drug metabolism. 
4.3.2. Benzydamine and FMO 
In the present work, we have also investigated the pulmonary metabolism of 
benzydamine. Benzydamine N-oxygenation is catalyzed by FMO1 and FMO3 in 
human (Lang and Rettie, 2000a). The expression of FMO enzymes is complex and 
varies extensively with species, tissue, age and gender (Ripp et al., 1999, Hines, 2006, 
Phillips and Shephard, 2017). In our experiments using rat lung microsomes, rat lung 
tissue and after i.v. and i.a. administration, we could detect formation of the 
benzydamine N-oxide metabolite. In microsomes the calculated organ clearance for 
lung was approximately 35% of the liver clearance. The estimated lung clearance with 
PCLS model was very low. Furthermore, benzydamine clearance values obtained 
following i.v. and i.a. drug administration were comparable, indicating that in vivo, rat 
pulmonary metabolism of benzydamine was negligible. Although FMO3 expression is 
high in rat liver, in rat lung its expression is limited (Lattard et al., 2002a, Lattard et al., 
2002c). FMO1 expression in rat lung is known to be greater than FMO3 expression 
(Lattard et al., 2002c). Therefore, observed benzydamine N-oxide formation in lung is 
likely the result of metabolism by FMO1. It has previously been reported that FMO 
isoforms are thermally labile in the absence of NADPH (Fisher et al., 2002). The 
contribution of FMO and CYPs to benzydamine N-oxygenation in rat lung microsomes 
was determined using thermal inactivation and the nonspecific irreversible CYP 
inhibitor (ABT). Heat treatment led to the total abolishment of benzydamine N-oxide 
formation in rat lung microsomes whereas ABT had no impact. These results indicated 
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that, benzydamine N-oxygenation is predominantly catalyzed by FMO. 
The FMO2 isoenzyme is a special case among FMO isoenzymes. Although functional 
FMO2 enzyme is expressed in mouse lung, it is catalytically inactive in rat lung (Karoly 
and Rose, 2001, Lattard et al., 2002b). Interestingly, in human, FMO2 is not active in 
Caucasians and Asians as these populations possess the FMO2*2 allele that codes 
for a non-functional, truncated protein (Dolphin et al., 1998, Whetstine et al., 2000, 
Krueger et al., 2004). Conversely, 27% of African and 5% of Hispanic populations 
possess the FMO2*1 allele that codes for the full length, functional active enzyme 
(Henderson et al., 2008). Furthermore, FMO2 has been reported to be less heat labile 
compare to other FMO isoforms (Cashman, 2005, Hutzler and Zientek, 2016). 
Therefore, depending on the target population for the drug under investigation, care 
should be taken when predicting PK parameters for drugs that are primarily FMO 
substrate. 
4.3.3. Scaling parameters  
While hepatic scaling factors are well defined, the availability of similar information for 
the lung is relatively limited. For example, in the current study the microsomal protein 
content in rat lung was assumed to be 15 mg/g lung (one third of that in rat liver (45 
mg/g)), which is the only information found in the literature (Houston, 1994, Lakritz et 
al., 2000, Schmitz et al., 2008). Investigations into lung metabolism would benefit 
greatly from the development of pulmonary scaling factors in all relevant species. The 
abundance of metabolic enzymes can be measured by either immunochemistry 
techniques (if specific antibodies are available), gene expression (mRNA), or can be 
estimated by the use of specific enzyme substrates and inhibitors. Correct information 
about abundance of the enzymes will certainly provide more accurate in vitro clearance 
estimates. Furthermore, an in vitro in vivo extrapolation (IVIVE) method for metabolic 
clearance in lung needs to be established.  
4.3.4. Relevance of pulmonary metabolism 
At the end of the research project, it is important to answer the question “when is 
pulmonary metabolism relevant and when should we use the optimized PCLS model”. 
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The liver is the primary organ of metabolism and the lung metabolic functionality and 
capacity rarely exceed the hepatic function. However, if the total body clearance 
exceeds the liver blood flow, this can be an indication for extrahepatic metabolism 
(Kanto and Gepts, 1989). Inhaled compounds such as anesthesia drugs are more 
likely to be metabolized by pulmonary enzymes, as they are directly exposed to the 
lungs. Hence, lung tissue could have a significant impact on the disposition of inhaled 
drugs.  
Pulmonary metabolism may have several consequences including decreased 
systemic exposure to the drug and the generation of site-specific reactive metabolites, 
which may lead to organ specific toxicity. Therefore, the investigation of pulmonary 
metabolism is relevant for the evaluation of safety and efficacy in drug discovery and 
development. Some prodrugs such as the inhaled corticosteroid, ciclesonide are 
designed to be metabolized in the lung tissue to yield an active metabolite (Nave et 
al., 2006, Nave et al., 2010). Investigations into pulmonary metabolism are crucial in 
cases such as these and PCLS is an appropriate model for the assessment of 
compounds developed for inhaled administration. For example, PCLS has previously 
been used to demonstrate that ciclesonide undergoes hydrolysis and reversible 
conjugation with fatty acids (FA) such as oleic acid in human lung (Nave et al., 2006, 
Nave et al., 2010) 
The time course of drug response for dosing regimens can be estimated using 
physiologically based pharmacokinetic (PBPK) models combined with 
pharmacodynamic (PD) models (Jones et al., 2015). Although the application of PBPK 
modelling to orally inhaled drugs has strongly increased in recent years, they currently 
concerned with understanding the absorption process (Borghardt et al., 2015). For 
example, to what extent do factors such as regional lung particle deposition and drug 
disposition processes influence free tissue drug concentrations (Backman et al., 2018). 
However, these models currently ignore the issue of pulmonary metabolism and its 
potential impact on safety and efficacy. Further investment is required in this area and 
the PCLS model may be a suitable system to support the development of mechanistic 
PBPK models for this purpose.  
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